The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model

Minimal residual disease (MRD) has become an increasingly prevalent and important entity in multiple myeloma (MM). Despite deepening responses to frontline therapy, roughly 75% of MM patients never become MRD-negative to ≤10(−5), which is concerning because MRD-negative status predicts significantly...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: O’Steen, Shyril, Comstock, Melissa L., Orozco, Johnnie J., Hamlin, Donald K., Wilbur, D. Scott, Jones, Jon C., Kenoyer, Aimee, Nartea, Margaret E., Lin, Yukang, Miller, Brian W., Gooley, Theodore A., Tuazon, Sherilyn A., Till, Brian G., Gopal, Ajay K., Sandmaier, Brenda M., Press, Oliver W., Green, Damian J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6788008/
https://ncbi.nlm.nih.gov/pubmed/31395601
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019001250
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados